The global migraine therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of migraine, rising awareness about the disease and its treatment, and growing demand for non-invasive treatments.
The specific antmigraine drugs segment accounted for the largest share in the global migraine therapeutics market in 2018. This segment is expected to continue its dominance throughout the forecast period owing to their efficacy and safety profile. Acute therapies are projected to be one of the fastest-growing segments in this market during 2020-2030 due to their ease of use and availability over-the-counter (OTC). Preventative therapies are also projected to grow at a significant rate during 2020-2030 due to their ability in preventing migraines from occurring or recurring.
-The global market for migraine therapeutics was valued at $2.5 billion in 2015 and is expected to reach $3.6 billion by 2020, growing at a compound annual growth rate (CAGR) of 4%.
-In the US, the prevalence of migraines has been estimated to be around 12% among adults aged 18 years or older with women being more likely than men to experience migraines.
Industry Growth Insights published a new data on “Migraine Therapeutics Market”. The research report is titled “Migraine Therapeutics Market research by Types (Specific Anti-migraine Drugs, Acute Therapies, Preventative Therapies, Other, Migraine Therapeutic), By Applications (Hospitals, Clinics, Household Use, Others), By Players/Companies Allergan, Merck, Pfizer, Teva, Amgen, Johnson & Johnson, Endo International, GlaxoSmithKline, Impax, Abbott, Bayer, Eli Lilly, Novartis International, Ethypharm, Kowa Pharmaceuticals America, Winston Pharmaceuticals, AstraZeneca, Amirall, OptiNose, Revance Therapeutics, RedHill Biopharma, Bausch Health, NeurAxon, Biohaven Pharma, Eisai, Valeant Pharma, Migraine Therapeutic”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Migraine Therapeutics Market Research Report
By Type
Specific Anti-migraine Drugs, Acute Therapies, Preventative Therapies, Other, Migraine Therapeutic
By Application
Hospitals, Clinics, Household Use, Others
By Companies
Allergan, Merck, Pfizer, Teva, Amgen, Johnson & Johnson, Endo International, GlaxoSmithKline, Impax, Abbott, Bayer, Eli Lilly, Novartis International, Ethypharm, Kowa Pharmaceuticals America, Winston Pharmaceuticals, AstraZeneca, Amirall, OptiNose, Revance Therapeutics, RedHill Biopharma, Bausch Health, NeurAxon, Biohaven Pharma, Eisai, Valeant Pharma, Migraine Therapeutic
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Migraine Therapeutics Market Report Segments:
The global Migraine Therapeutics market is segmented on the basis of:
Types
Specific Anti-migraine Drugs, Acute Therapies, Preventative Therapies, Other, Migraine Therapeutic
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Household Use, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan
- Merck
- Pfizer
- Teva
- Amgen
- Johnson & Johnson
- Endo International
- GlaxoSmithKline
- Impax
- Abbott
- Bayer
- Eli Lilly
- Novartis International
- Ethypharm
- Kowa Pharmaceuticals America
- Winston Pharmaceuticals
- AstraZeneca
- Amirall
- OptiNose
- Revance Therapeutics
- RedHill Biopharma
- Bausch Health
- NeurAxon
- Biohaven Pharma
- Eisai
- Valeant Pharma
- Migraine Therapeutic
Highlights of The Migraine Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Specific Anti-migraine Drugs
- Acute Therapies
- Preventative Therapies
- Other
- Migraine Therapeutic
- By Application:
- Hospitals
- Clinics
- Household Use
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Migraine Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Migraine Therapeutics is a global biopharmaceutical company focused on the development and commercialization of novel treatments for migraine. The company's lead product candidate, erenumab (erenumab pegol), is an investigational monoclonal antibody that has been shown to be effective in the treatment of migraine.
Some of the major players in the migraine therapeutics market are Allergan, Merck, Pfizer, Teva, Amgen, Johnson & Johnson, Endo International, GlaxoSmithKline, Impax, Abbott, Bayer, Eli Lilly, Novartis International, Ethypharm, Kowa Pharmaceuticals America, Winston Pharmaceuticals, AstraZeneca, Amirall, OptiNose, Revance Therapeutics, RedHill Biopharma, Bausch Health, NeurAxon, Biohaven Pharma, Eisai, Valeant Pharma, Migraine Therapeutic.
The migraine therapeutics market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Migraine Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Migraine Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Migraine Therapeutics Market - Supply Chain
4.5. Global Migraine Therapeutics Market Forecast
4.5.1. Migraine Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Migraine Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Migraine Therapeutics Market Absolute $ Opportunity
5. Global Migraine Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Migraine Therapeutics Market Size and Volume Forecast by Type
5.3.1. Specific Anti-migraine Drugs
5.3.2. Acute Therapies
5.3.3. Preventative Therapies
5.3.4. Other
5.3.5. Migraine Therapeutic
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Migraine Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Migraine Therapeutics Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Household Use
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Migraine Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Migraine Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Migraine Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Migraine Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Migraine Therapeutics Demand Share Forecast, 2019-2026
9. North America Migraine Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Migraine Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Migraine Therapeutics Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Household Use
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Migraine Therapeutics Market Size and Volume Forecast by Type
9.7.1. Specific Anti-migraine Drugs
9.7.2. Acute Therapies
9.7.3. Preventative Therapies
9.7.4. Other
9.7.5. Migraine Therapeutic
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Migraine Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Migraine Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Migraine Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Migraine Therapeutics Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Household Use
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Migraine Therapeutics Market Size and Volume Forecast by Type
10.7.1. Specific Anti-migraine Drugs
10.7.2. Acute Therapies
10.7.3. Preventative Therapies
10.7.4. Other
10.7.5. Migraine Therapeutic
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Migraine Therapeutics Demand Share Forecast, 2019-2026
11. Europe Migraine Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Migraine Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Migraine Therapeutics Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Household Use
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Migraine Therapeutics Market Size and Volume Forecast by Type
11.7.1. Specific Anti-migraine Drugs
11.7.2. Acute Therapies
11.7.3. Preventative Therapies
11.7.4. Other
11.7.5. Migaine Therapeutic
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Migraine Therapeutics Demand Share, 2019-2026
12. Asia Pacific Migraine Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Migraine Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Migraine Therapeutics Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Household Use
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Migraine Therapeutics Market Size and Volume Forecast by Type
12.7.1. Specific Anti-migraine Drugs
12.7.2. Acute Therapies
12.7.3. Preventative Therapies
12.7.4. Other
12.7.5. Migraine Therapeutic
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Migraine Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Migraine Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Migraine Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Migraine Therapeutics Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Household Use
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Migraine Therapeutics Market Size and Volume Forecast by Type
13.7.1. Specific Anti-migraine Drugs
13.7.2. Acute Therapies
13.7.3. Preventative Therapies
13.7.4. Other
13.7.5. Migraine Therapeutic
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Migraine Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Migraine Therapeutics Market: Market Share Analysis
14.2. Migraine Therapeutics Distributors and Customers
14.3. Migraine Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Allergan
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Teva
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Amgen
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Johnson & Johnson
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Endo International
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. GlaxoSmithKline
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Impax
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Abbott
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Bayer
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Eli Lilly
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Novartis International
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Ethypharm
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Kowa Pharmaceuticals America
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Winston Pharmaceuticals
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. AstraZeneca
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Amirall
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. OptiNose
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. Revance Therapeutics
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
